6/19/18. Emerging Challenges in Primary Care: The Progression of Type 2 Diabetes: A Rational Approach for Long-term Disease Management.
|
|
- Andra Wood
- 5 years ago
- Views:
Transcription
1 Emerging Challenges in Primary Care: 2018 The Progression of Type 2 Diabetes: A Rational Approach for Long-term Disease Management 1 Rodolfo J. Galindo, MD Faculty Assistant Professor of Medicine Emory University School of Medicine Principal Investigator, Center for Diabetes and Metabolism Research Division of Endocrinology, Diabetes and Metabolism Emory University Hospital Midtown Medical Chair, Hospital Diabetes Taskforce Emory Healthcare System Atlanta, GA Javier Morales, MD, FACP, FACE Clinical Associate Professor of Medicine Donald and Barbara Zucker School of Medicine at Hofstra/Northwell University Vice President, Advanced Internal Medicine Group, P.C. East Hills, NY 2 Faculty Leann Olansky, M D, FA C P, FA C E Department of Endocrinology, Diabetes and Metabolism Endocrinology & Metabolism Institute Cleveland Clinic Cleveland, OH Mark Stolar, M D Associate Professor of Clinical Medicine Feinberg School of Medicine Northwestern University Chicago, IL Jeff Unger, MD, FAAFP, FACE Assistant Clinical Professor of Family Medicine UC Riverside School of Medicine Director, Unger Concierge Primary Care Medical Group Rancho Cucamonga, CA 3 1
2 Disclosures Rodolfo J. Galindo, MD has no relevant financial relationships to disclose. Javier Morales, MD, FACP, FACE serves on the speakers bureau and as a consultant for Lilly, Novo Nordisk, Janssen, and Abbott. Leann Olansky, M D, FA C P, FA C E has no relevant financial relationships to disclose. Mark Stolar, M D serves on the speakers bureau for Astra Zeneca. Jeff Unger, MD, FAAFP, FACE serves as a consultant, researcher and advisory board member for Novo Nordisk, Janssen, and Abbott Diabetes. 4 Learning Objectives Recognize the pathogenesis of type 2 diabetes (T2D) as a progressive, multi-defect disorder Discuss the strengths and limitations of current guidelines for diabetes management Successfully use strategies for adherence to multiple medications to improve outcomes in diabetes Examine data on current combination strategies to choose therapies that most effectively address a patient s underlying pathophysiologic needs 5 PRE-TEST QUESTIONS
3 Please rate your confidence in your ability to manage T2D as a multi-defect disorder with individualized combination therapy: 1. Not at all confident 2. Slightly confident 3. Moderately confident 4. Pretty much confident 5. Very confident Pre-test ARS Question 1 7 Pre-test ARS Question 2 How often do you select antidiabetic therapy based on its mechanism of action? 1. Never 2. Rarely 3. Sometimes 4. Often 5. Always 8 Pre-test ARS Question 3 Approximately how many patients with Diabetes do you see on a weekly basis, in any clinical setting? 1. None >25 9 3
4 Progressive β-cell Dysfunction Is a Key Driver of Progressive Dysglycemia in T2D By diabetes onset, up to 80% of β-cell function may be lost1,2 Insulin Resistance Decreasing β-cell function partially driven by incretin defect PPG FPG Normal Impaired Glucose Glucose Tolerance Tolerance Insulin Secretion β-cell Function Diagnosis Severity of Glucose Intolerance Time in Years PPG=postprandial 1. Defronzo RA. Diabetes. plasma 2009;58: glucose; FPG=fasting 2. FehseF, plasma et glucose. al. J Clin Endocrinol Metab. 2005;90: Figure adapted from Kendall DM, et al. Am J Med.2009;122(6 Supp):S37-S ARS Question 4 All of the following are pathophysiologic mechanisms of T2D, EXCEPT: 1. Increased lipolysis 2. Decreased incretin effect 3. Decreased glucagon secretion 4. Increased glucose reabsorption 11 Ominous Octet DeFronzo RA. Diabetes. 2009;58:
5 ARS Question 5 According to current AACE and ADA guidelines, which therapy should be considered for a patient with symptoms of hyperglycemia at diagnosis of T2D? 1. Metformin monotherapy 2. Metformin plus 1 other antidiabetic drug 3. Metformin plus 2 other antidiabetic drugs 4. Basal insulin +/- other antidiabetic drugs ADA Standards of Care in Diabetes DPP-4i, dipeptidyl peptidase-4 inhibitor; SGLT2i, sodium-glucose cotransporter 2 inhibitor; GLP-1 RA, glucagonlike 1):S1 S159. peptide-1 receptor agonist; SU, sulfonylurea; TZD, thiazolidinedione. ADA. Diabetes Care. 2018;41(Suppl. 14 AACE: Glycemic Control Algorithm 15 5
6 Mechanism Decreased hepatic glucose production. May not be sensitizer. Decreased intestinal glucose absorption Advantages No weight gain or hypoglycemia Disadvantages Biguanides: Metformin Gastrointestinal side effects Renal function monitoring GFR<45ml/min/1.73m2è 1000mg/day GFR<30ml/min/1.73m2è discontinue Vitamin B12 deficiency accessed July Discussion Points When Intensifying Pharmacotherapy Tx intensification needed because diabetes is progressive, not because of patient non-compliance. Maintaining A1C 6%-6.5% for 4-6 years after diagnosis induces metabolic memory and the legacy effect. Complications are reduced. Tx options are based on disease duration. Longer duration = lower beta-cell mass and function. Frequency, timing and route of administration should be clearly defined. Discuss risks and benefits of all meds prescribed. Excellent composite endpoint would be to achieve target A1C without weight gain or hypoglycemia. Unger J. Diabetes Management In Primary Care. Lippincott Factors to Guide Therapeutic Choices When A1C Not at Goal Age If younger, durability of therapy/beta-cell impact important If older, safety essential Comorbidity Risks of hypoglycemia Absolute risk of known side effect profile vs reported risk Mechanism of What isn t being treated currently? action What is ineffective? Clinical clues Acanthosis, low HDL, hypertriglyceridemia markers of insulin resistance Leaner body weight = likelihood of beta cell dysfunction SMBG PBG better guide than FBG when A1C <8.0% 18 6
7 Consequences of Delayed Intervention A1C % Patients with A1C 7% not receiving IT w ithin 1 year Patients with A1C <7% who received IT before 1 year of diagnosis At 5.3 years, increased risks: - MI 67% (95% CI: 39%,101%) - Stroke 51% (95% CI: 25%, 83%) - HF 64% (95% CI: 40%, 91%) - Composite CVE 62% (95% CI: 46%, 80%) Bad glycemic legacy Drives risk for complications Months CVE = cardiovascular endpoint; HF = heart failure; IT = treatment intensification; MI = myocardial infarction Paul S et al. Cardiovasc Diabetol 2015;14:100 doi: /s x 19 Add-on Therapy: What Comes After Metformin? Joe was diagnosed with diabetes 1 year ago He was started on metformin when his A1C was 8.0% Despite trying his hardest at weight loss and physical activity, his weight is the same and A1C remains 7.5% What factors guide you as to next steps for therapy? Should Joe have started combination therapy at diagnosis? If so, what combination? 20 Questions to Consider 21 7
8 Sulfonylureas and Glitinides Cheap Advantages Oral Effective for patients with MODY (Monogenetic Diabetes) Disadvantages Hypoglycemia risk Elderly and CKD Weight gain Myocardial ischemic preconditioning, increases MI risk after PCI (glyburide) Loss of durability in every clinical trial Glitinides must be taken ½ hour before meals Unger J. Diabetes Management In Primary Care. Lippincott Thiazolidinediones (TZD):Pioglitazone Advantages No hypoglycemia Cheap Can prevent progression of prediabetes to clinical diabetes Durability of effect Favorable beta cell function Only muscle and adipocyte insulin sensitizer May reduce NASH Favorable TG and HDL effects Disadvantages Weight gain Edema Cannot use in patients with HF Bone fractures? Bladder cancer 23 DPP-4 Inhibitors Advantages Enhance glucosedependent insulin secretion Decrease glucagon secretion** inappropriate Oral, once daily Very low side effect profile Weight neutral No apparent CV risk (saxagliptin, alogliptin, sitagliptin) Disadvantages Cost Efficacy Pancreatitis warning Durability?? Heart failure (saxagliptin,alogliptin) Same mechanism but significantly less efficacy than GLP-1 RA 24 8
9 GLP-1 Receptor Agonists Advantages Enhance glucose dependent insulin secretion Decrease inappropriate glucagon secretion Low risk of hypoglycemia Single dose effect on beta cell function Superior efficacy compared to orals Weight loss CVD safety / benefit Disadvantages Cost Injection/injection site issues Nausea Pancreatitis warning (no longer for liraglutide and dulaglutide) MTC warning 25 GLP-1 RA Pharmacologic Activity Higher with GLP-1 RAs than DPP-4 N=61 metformin- treated, e v a lu a b le p a tie n ts 2 - Hour Postprandial Plasma GLP- 1 Concentration ( pm ) Baseline 7 Sitagliptin once daily 15 Endogenous GLP-1 Activity Plasma GLP-1 Exenatide tw ice d a ily 64 Added GLP-1 RA Activity Plasma Exenatide Concentration (pm ) 2 - Hour Plasma Exenatide DeFronzo RA, et al. Curr Med Res Opin. 2008;24(10): Incretin Therapies to Treat T2DM Incretin effect is impaired in T2D Natural GLP-1/GIP have extremely short half-lives Add GLP-1 analogues with longer half-life: Exendin-4 Based: Exenatide Exenatide QW Lixisenatide Injectables Human GLP-1: Liraglutide Semaglutide Dulagutide Oral agents Block DPP-4, the enzyme that degrades GLP-1: Sitagliptin Saxagliptin Linagliptin Alogliptin Drucker. Curr Pharm Des. 2001;7(14): Drucker. Mol Endocrinol. 2003;17(2):
10 Only About One-third of Patients Are Adherent to GLP-1 RAs POORLY ADHERENT ADHERENT 34% Adherent with GLP-1 RA QD over 1 year of treatment Claims database study of 1321 patients with T2D treated with lira g lu tid e qd Adherence defined as PDC 0.8 Buysman EK, et al. Adv Ther. 2015;32: Glucoretic Based Therapies SGLT 2 Inhibitors Agents Canagliflozin Dapagliflozin Empagliflozin Ertugliflozin Advantages Effectiveness independent of insulin Low risk for hypoglycemia Small amount of weight loss Modest reduction in blood pressure Possible favorable CV/renal outcomes Disadvantages Adequate renal function/monitoring required Amputation risk increased Euglycemic DKA Cost Diabetes Care 2014;37: S Normal Glucose Homeostasis Net balance ~ 0 g/day Glucose input ~250 g/day: Glucose uptake ~250 g/day: Dietary intake ~180 g/d Glucose production ~70 g/d Gluconeogenesis Glycogenolysis + Kidney filters circulating glucose Glucose filtered ~180 g/day Brain ~125 g/d Rest of the body ~125 g/d Kidney reabsorbs and recirculates glucose Glucose reabsorbed ~180 g/day 30 10
11 SGLT-2 Inhibitors: Mechanism of Action (cont) Free Filtration of Solute Active Reabsorption Glucose SGLT-2 SGLT-1 Glucose Juxtoglomerular Complex Proximal Convoluted Tubules Loop of Henle Type 2 Diabetes 31 Empa 10, 25 mg or standard of care EMPA-REG Trial Death from a CV event, non-fatal MI, or stroke Patients With Event, % Patients With Event, % Patients With Event, % Cumulative Incidence of the Primary Outcomea P =0.04 for superiority Hazard ratio, 0.86 (95.02% CI, ) Placebo Empagliflozin Cumulative Incidence of Death From CV Causes Placebo P <0.001 Hazard ratio, 0.62 (95% CI, ) 38% risk reduction Empagliflozin % risk reduction 35% risk reduction P =0.002 Hospitalization for Heart Failure Hazard ratio, 0.65 (95% CI, ) Placebo Empagliflozin Month acumulative incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. N=7020 patients with T2DM at high risk of cardiovascular events. Zinman B, et al. N Engl J Med. 2015;373(22): Empa-Reg Renal Data Warner C, et al. NEJM. DOI: /NEJMoa
12 Why Not Use Insulin as Add-on Therapy? Effective means of insulin-providing therapy Most potent A1C reductions Indicated as add-on to monotherapy when A1C above 8.5% Hypoglycemia and weight gain are barriers but insulin itself does not cause weight gain metabolically Bedtime NPH, basal insulin or ultralong-acting basal insulins provide varying cost options as add-on therapy, with differences in hypoglycemia and weight gain 34 Barriers to Multimolecular Therapy Adherence Hypoglycemia Underutilization of combination meds 35 Medication Adherence in T2D Medication adherence rates are ~45% among diabetics ~1/3 of all initial prescriptions for glucose-lowering agents go unfilled Non-adherence increases likelihood of long-term complications / negative glycemic legacy and risk of hospitalization Hospitalization risk is 30% at the lowest quintile of adherence vs. 13% in highest quintile 36 12
13 Improving Patient Adherence Discussion between patients and clinicians related to risk:benefit ratio is critical Choose therapies that reduce risk of hypoglycemia and weight gain Hypoglycemia risk increases with duration of disease and age Hypoglycemia increases risk of mortality Consider use of drugs that may improve CV outcomes (death from MI, nonfatal MI, stroke, CHF) and/or renal disease progression Decisions that are patient-centered are likely to improve clinical outcomes Garcia-Perez et al. Diabetes Ther. 2013;4: Meet Edward: A 45 y/o Man with T2D 45 y/o Hispanic male with 2-year history of T2D Currently on metformin 1000 mg BID A1C 7.3% 1 year ago, 7.6% 3 months ago, and 8.0% today Obese (BMI 33.7 kg/m 2 ), sedentary, diet very high in carbohydrates Says he is unlikely to modify his lifestyle soon PE: Normal except for acanthosis nigricans SMBG shows average FBG 140mg/d but PBG >200mg/dL 38 ARS Question What Is Happening Physiologically with Edward? 1. Beta-cell function is declining 2. Metformin is not providing adequate insulin sensitivity 3. Lifestyle nonadherence is main reason for his increasing blood glucose 4. Impact on weight is more important than durability of action in choosing next therapy for this patient 5. 1 and
14 ARS Question: What Would You Add Next? 1. Basal insulin 2. Combination oral agent 3. DPP-4 inhibitor 4. GLP-1 RA 5. Pioglitazone 6. Secretagogue 7. SGLT-2 inhibitor 40 Andy: 54 y/o with CAD and T2D 54 y/o man with 3-year history of T2D Controlled on metformin 850 bid and glimepiride 1 mg A1C has ranged from 7.1% to 7.3% Last year, hospitalized for NSTEMI; found to have grade 1 diastolic dysfunction and grade 1 right carotid bruit that did not require intervention At a recent office visit, A1C had risen to 7.8% with no changes in diet, activity, or weight Reports 2 episodes of hypoglycemia while on the golf course but attributed them to missing lunch 41 Considerations in Intensifying Therapy in Patients with CAD Impact of hypoglycemia risk on CV risk Impact on cardiometabolic risk factors Impact on CV outcomes (liraglutide, empagliflozin) Impact on CNS/Stroke outcomes (semaglutide, pioglitazone) What s the best change in therapy for Andy? 42 14
15 Hypoglycemia and Cardiovascular Risk Desouza CV et al. Diabetes Care. 2010;33: CV Outcomes Trials for GLP-1 RAs Trial Agent Complete FREEDOM- CVO Exenatide ICTA REWIND NCT Dulaglutide 2019 EXSCEL NCT LEADER1 NCT Exenatide QW 2017 Liraglutide 2016 ELIXA2 NCT Lixisenatide 2014 SUSTAIN-63 NCT Semaglutide MarsoSP. N Engl J Med Sep 16; 375: Pfeffer M. N Engl J Med Dec 3;373(23): Phase 3 safety trial meets primary & secondary endpoints demonstrating non-inferiority for cardiovascular (C V ) safety with exenatide qw / m icropum p 13% reduction in first occurrence of death from CV causes, death from any causes, nonfatal MI, or nonfatal stroke with liraglutide No increased risk for CV death, heart attack, stroke, unstable angina, or heart failure in people with T2DM and recent acute coronary syndrom e with lixisenatide 26% reduction in C V death, nonfatal MI, or nonfatal stroke was significantly lower among patients (at high CV risk) with semaglutide versus placebo 44 Shavante: 39 y/o on Multiple Meds 39 y/o with 4-year history T2D Had gestational diabetes with last 2 pregnancies but was diabetes-free for 4 years Initially treated with metformin 1000 mg bid, then added glimepiride 4 mg, and finally sitagliptin 100 mg Only has time to exercise 1 day/week; diet is affected by what her kids will eat At last 2 visits, A1C 8.4% and weight stable at 238 lbs Average FBG 130 mg/dl Doesn t check later in the day because those numbers were too high when she did check 45 15
16 ARS Question 6 What might be an appropriate next step for Shavante? 1. Add pioglitazone and/or SGLT-2 inhibitor 2. Discontinue all oral agents and initiate basal-bolus insulin 3. Discontinue glimepiride and sitagliptin and start 2 alternative oral antidiabetic agents 4. Enhance adherence by initiating once weekly GLP-1 RA or daily combined basal insulin/glp-1 RA 46 Basal insulin analogs GLP-1 RA + Basal Insulin Simple to initiate Control nocturnal hyperglycemia Control FPG Less hypoglycemia risk vs NPH Can cause weight gain Achieve A1C target in ~50%a Simple to initiate Can control FPG and PPG GLP-1 RAs Do not impair α-cell response to hypoglycemia (reduce severe hypoglycemia) Reduce weight Achieve A1C target in ~60%a Insulin degludec/liraglutide (DEG-LIRA), insulin glargine/lixisenatide (GLAR-LIXI) combinations FDA-approved 1. Buse JB, et al. Diabetes Obes Metab. 2015;17(2): Holst JJ, Vilsbøll T. Diabetes Obes Metab. 2013;15(1): Vora J, et al. Diabetes Metab. 2013;39(1): Recommendations for GLP-1 RA with Basal Insulin GLP-1 RA may be used in combination with basal insulin in patients who do not reach glycemic target with 2-3 glucose-lowering medications 1-4 If taking a sulfonylurea (SU), consider discontinuing or reducing the dose of SU If adding GLP-1RA to basal insulin, consider reducing basal insulin dose 20% if A1C 8.0% Thereafter, adjust basal insulin dose based on selfmonitoring of blood glucose especially in first six weeks post insulin dose reduction Monitor for hypoglycemia 1. Inzucchi SE, et al. Diabetes Care. 2015;38: American Diabetes Association. Diabetes Care. 2017;40(suppl 1):S1-S Handelsman Y, et al. Endocr Pract. 2015;21(suppl 1): Garber AJ, et al. Endocr Pract. 2015;21:e1-e
17 -1-2 Basal Insulin/GLP-1 RA Fixed-ratio Coformulations A1C < 7%, % 81 60* 65* Change in Change in A1C, % Body Weight, kg DEG-LIRA DEG LIRA GLAR-LIXI DEG-LIRA noninferior to DEG and superior to LIRA (26-week open-label, treat-to-target RCT; N=1663 [insulin naïve]) * GLAR GLAR-LIXI superior to GLAR (24-week open-label, treat-to-target RCT; N=323 [insulin naïve]) * 3 severe hypoglycemic episodes per group Lower rate of hypoglycemia for LIRA vs DEG or DEG-LIRA (overall and nocturnal)1 Lower rate of hypoglycemia for GLAR-LIXI than for GLAR (overall)2,e Individual GLP-1 RAs should not be mixed with or injected adjacent to insulin3 *P<0.001 vs DEG-LIRA; P<0.001 vs GLAR-LIXI. RCT=randomized controlled trial. 1. Gough SC, et al. Lancet Diabetes Endocrinol. 2014;2: Rosenstock J, et al. Diabetologia. 2014;57(suppl 1) [abstract 241]. 3. US FDA. Drugs@FDA. Accessed August 23, e P <.001 vs GLAR-LIXI 49 Principles of Multimolecular Therapy Metformin remains foundation of therapy but is not universally effective in all patients, especially those who are insulin deficient Look for untreated mechanistic targets and add accordingly Remove any medications that are not providing expected therapeutic benefit Reconsider pioglitazone for the insulin-resistant patient Metformin is NOT the sensitizer we once thought, though very effective in lowering glucose overall Look to GLP-1 RA and SGLT-2 in insulin-deficient patients and always look to add insulin earlier instead of additional oral agents 50 POST-TEST QUESTIONS
18 Post-test ARS Question 1 After completing this activity, please rate your confidence now in your ability to manage T2D as a multi-defect disorder with individualized combination therapy: 1. Not at all confident 2. Slightly confident 3. Moderately confident 4. Pretty much confident 5. Very confident 52 Post-test ARS Question 2 After completing this activity, how often do you intend to select antidiabetic therapy based on its mechanism of action? 1. Never 2. Rarely 3. Sometimes 4. Often 5. Always 53 Post-test ARS Question 3 All of the following are pathophysiologic mechanisms of T2D, EXCEPT: 1. Increased lipolysis 2. Decreased incretin effect 3. Decreased glucagon secretion 4. Increased glucose reabsorption 54 18
19 Post-test ARS Question 4 According to current AACE and ADA guidelines, which therapy should be considered for a patient with symptoms of hyperglycemia at diagnosis of T2D? 1. Metformin monotherapy 2. Metformin plus 1 other antidiabetic drug 3. Metformin plus 2 other antidiabetic drugs 4. Basal insulin +/- other antidiabetic drugs 55 Post-test ARS Question 5: Shavante 39 y/o with 4-year history T2D Had gestational diabetes with last 2 pregnancies but was diabetes-free for 4 years Initially treated with metformin 1000 mg bid, then added glimepiride 4 mg, and finally sitagliptin 100 mg Only has time to exercise 1 day/week; diet is affected by what her kids will eat At last 2 visits, A1C 8.4% and weight stable at 238 lbs Average FBG 130 mg/dl Doesn t check later in the day because those numbers were too high when she did check 56 Post-test ARS Question 5 Cont d What might be an appropriate next step for Shavante? 1. Add pioglitazone and/or SGLT-2 inhibitor 2. Discontinue all oral agents and initiate basalbolus insulin 3. Discontinue glimepiride and sitagliptin and start 2 alternative oral antidiabetic agents 4. Enhance adherence by initiating once weekly GLP-1 RA or daily combined basal insulin/glp-1 RA 57 19
20 Questions? 58 20
Emerging Challenges in Primary Care: The Progression of Type 2 Diabetes: A Rational Approach for Long-term Disease Management
Emerging Challenges in Primary Care: 2018 The Progression of Type 2 Diabetes: A Rational Approach for Long-term Disease Management 1 Faculty Rodolfo J. Galindo, MD Assistant Professor of Medicine Emory
More information5/24/18. Emerging Challenges in Primary Care: The Progression of Type 2 Diabetes: A Rational Approach for Long-term Disease Management.
Emerging Challenges in Primary Care: 2018 The Progression of Type 2 Diabetes: A Rational Approach for Long-term Disease Management Faculty Rodolfo J. Galindo, MD Assistant Professor of Medicine Emory University
More informationCardiovascular Benefits of Two Classes of Antihyperglycemic Medications
Cardiovascular Benefits of Two Classes of Antihyperglycemic Medications Nathan Woolever, Pharm.D., Resident Pharmacist Pharmacy Grand Rounds November 6 th, 2018 Franciscan Healthcare La Crosse, WI 2017
More informationType 2 Diabetes Management: Case 1: Reducing Hypoglycemic Risk Case 2: Reducing Cardiovascular Risk
Type 2 Diabetes Management M. Susan Burke, MD, FACP Clinical Associate Professor of Medicine Sidney Kimmel Medical College at Thomas Jefferson University Senior Advisor, Lankenau Medical Associates Lankenau
More informationGLP 1 agonists Winning the Losing Battle. Dr Bernard SAMIA. KCS Congress: Impact through collaboration
GLP 1 agonists Winning the Losing Battle Dr Bernard SAMIA KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures I have
More informationCase Studies in Type 2 Diabetes Mellitus: Focus on Cardiovascular Outcomes Trials
Case Studies in Type 2 Diabetes Mellitus: Focus on Cardiovascular Outcomes Trials Louis Kuritzky MD Clinical Assistant Professor Emeritus Department of Community Health and Family Medicine College of Medicine
More informationDM-2 Therapy Update: GLP-1, SGLT-2 Inhibitors, and Inhaled Insulin, Oh My!
DM-2 Therapy Update: GLP-1, SGLT-2 Inhibitors, and Inhaled Insulin, Oh My! Kevin M. Pantalone, DO, ECNU, CCD Associate Staff Director of Clinical Research Department of Endocrinology Endocrinology and
More informationOral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy
Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 7, 2012 VanderbiltHeart.com Outline
More informationCan We Reduce Heart Failure by Treating Diabetes? CVOT Data on SGLT2 Inhibitors and GLP-1Receptor Agonists
Can We Reduce Heart Failure by Treating Diabetes? CVOT Data on SGLT2 Inhibitors and GLP-1Receptor Agonists Robert R. Henry, MD Professor of Medicine University of California, San Diego Relevant Conflict
More informationIncretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
Incretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors Timothy Bailey, MD, FACE, CPI Director, AMCR Institute,
More informationManagement of Type 2 Diabetes Cardiovascular Outcomes Trials Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas
Management of Type 2 Diabetes Cardiovascular Outcomes Trials 2018 Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas Speaker Disclosure Dr. Blevins has disclosed that he has received grant support
More informationThe Many Faces of T2DM in Long-term Care Facilities
The Many Faces of T2DM in Long-term Care Facilities Question #1 Which of the following is a risk factor for increased hypoglycemia in older patients that may suggest the need to relax hyperglycemia treatment
More informationBeyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM
Beyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM Disclosures Jennifer D Souza has no conflicts of interest to disclose. 2 When Basal Insulin Is Not Enough Learning
More informationEarly treatment for patients with Type 2 Diabetes
Israel Society of Internal Medicine Kibutz Hagoshrim, June 22, 2012 Early treatment for patients with Type 2 Diabetes Eduard Montanya Hospital Universitari Bellvitge-IDIBELL CIBERDEM University of Barcelona
More informationCardiovascular Outcomes With Newer Diabetes Drugs: Results From The EMPA-REG and LEADER Trials
Cardiovascular Outcomes With Newer Diabetes Drugs: Results From The EMPA-REG and LEADER Trials Rajiv Roy, MD Endocrinology Sharp Rees-Stealy Medical Group Background Between 1990 and 2010: Incidence of
More informationSodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol
Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has
More informationThe Death of Sulfonylureas? A Review of New Diabetes Medications
The Death of Sulfonylureas? A Review of New Diabetes Medications Kelly Hoenig, Pharm.D., BCPS Cedar Rapids Family Medicine Residency 2/4/17 Objectives Review GLP-1 Agonists, DPP-IV Inhibitors and SGLT-2
More informationNEW DIABETES CARE MEDICATIONS
NEW DIABETES CARE MEDICATIONS James Bonucchi DO, ECNU, FACE Adult Medicine and Endocrinology Specialists Disclosures Speakers bureau Sanofi AZ BI Diabetes Diabetes cost ADA 2017 data Ever increasing disorder.
More informationUpdate on Diabetes Cardiovascular Outcome Trials
Update on Diabetes Cardiovascular Outcome Trials Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine
More informationCurrent principles of diabetes management
Current principles of diabetes management Prof. Martin Haluzík, MD, DSc. 3 Department of Medicine, General University Hospital and 1st Faculty of Medicine, Charles University in Prague, Czech Republic
More informationA Practical Approach to the Use of Diabetes Medications
A Practical Approach to the Use of Diabetes Medications Juan Pablo Frias, M.D., FACE President, National Research Institute, Los Angles, CA Clinical Faculty, University of California, San Diego, CA OUTLINE
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC Choosing the Right Agent for your Patient with diabetes: Individualizing type 2 diabetes management in light of the expanding therapies
More informationUpdate on Insulin-based Agents for T2D
Update on Insulin-based Agents for T2D Injectable Therapies for Type 2 Diabetes Mellitus (T2DM) and Obesity This presentation will: Describe established and newly available insulin therapies for treatment
More informationNo Increased Cardiovascular Risk for Lixisenatide in ELIXA
ON ISSUES IN THE MANAGEMENT OF TYPE 2 DIABETES JUNE 2015 Coverage of data from ADA 2015, June 5 9 in Boston, Massachusetts No Increased Cardiovascular Risk for Lixisenatide in ELIXA First Cardiovascular
More informationDiabetes: Three Core Deficits
Diabetes: Three Core Deficits Fat Cell Dysfunction Impaired Incretin Function Impaired Appetite Suppression Obesity and Insulin Resistance in Muscle and Liver Hyperglycemia Impaired Insulin Secretion Islet
More informationOral Agents. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK
Oral Agents Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What would your ideal diabetes drug do? Effective in lowering HbA1c No hypoglycaemia No effect on weight/ weight
More informationPharmacology Updates. Quang T Nguyen, FACP, FACE, FTOS 11/18/17
Pharmacology Updates Quang T Nguyen, FACP, FACE, FTOS 11/18/17 14 Classes of Drugs Available for the Treatment of Type 2 DM in the USA ### Class A1c Reduction Hypoglycemia Weight Change Dosing (times/day)
More informationWhat s New in Type 2 Diabetes? 2018 Diabetes Updates
What s New in Type 2 Diabetes? 2018 Diabetes Updates Gretchen Ray, PharmD, PhC, BCACP, CDE Associate Professor, UNM College of Pharmacy January 28, 2018 gray@salud.unm.edu OBJECTIVES Describe the most
More informationLATE BREAKING STUDIES IN DM AND CAD. Will this change the guidelines?
LATE BREAKING STUDIES IN DM AND CAD Will this change the guidelines? Objectives 1. Discuss current guidelines for prevention of CHD in diabetes. 2. Discuss the FDA Guidance for Industry regarding evaluating
More informationSESSION 4 12:30pm 1:45pm
SESSION 4 12:30pm 1:45pm Addressing Renal-Mediated Glucose Homeostasis: Diabetes and the Kidney SPEAKER Davida Kruger, MSN, BC-ADM, APRN Presenter Disclosure Information The following relationships exist
More informationIndividualizing Care for Patients with Type 2 Diabetes
Individualizing Care for Patients with Type 2 Diabetes Disclosures Speaker: AstraZeneca, Novo Nordisk, BI/Lilly, Valeritas, Takeda Advisor: Tandem Diabetes, Sanofi Objectives Develop individualized approaches
More informationObesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes
Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes Genetics, environment, and lifestyle (obesity, inactivity, poor diet) Impaired fasting glucose Decreased β-cell
More informationDIABETES DEBATE - IS NEW BETTER?
DIABETES DEBATE - IS NEW BETTER? WHAT MEDICATION CLASS AFTER METFORMIN TO CONTROL BLOOD SUGAR Dr. Lydia Hatcher, MD, CCFP, FCFP, CHE, D-CAPM Associate Clinical Professor of Family Medicine, McMaster Chief
More informationMultiple Factors Should Be Considered When Setting a Glycemic Goal
Multiple Facts Should Be Considered When Setting a Glycemic Goal Patient attitude and expected treatment effts Risks potentially associated with hypoglycemia, other adverse events Disease duration Me stringent
More information9/6/18. Clinical Updates for Nurse Practitioners and Physician Assistants: Faculty. Disclosures
Clinical Updates for Nurse Practitioners and Physician Assistants: 218 Combination Basal Insulin and GLP-1 RA Therapy: A Physiologic Approach to Diabetes Care Faculty Robert S. Busch, MD, FACE Director
More informationTerapia con agonisti GLP1 e outcome cardiovascolare. Edoardo Mannucci
Terapia con agonisti GLP e outcome cardiovascolare Edoardo Mannucci Conflitti di interessi Negli ultimi due anni, E. Mannucci ha ricevuto compensi per relazioni e/o consulenze da: Abbott, AstraZeneca,
More informationPHARMACOLOGIC APPROACH TO ACHIEVE GLYCEMIC GOAL
Dr Aurora Alcantara Endocrinology PHARMACOLOGIC APPROACH TO ACHIEVE GLYCEMIC GOAL SPED Convention and Diabetes Postgraduate Course May26-29 Wyndham Grand Rio Mar, PR DISCLOSURES Speaker for the following
More informationIDF Regions and global projections of the number of people with diabetes (20-79 years), 2013 and Diabetes Atlas -sixth Edition: IDF 2013
IDF Regions and global projections of the number of people with diabetes (20-79 years), 2013 and 2035 Diabetes Atlas -sixth Edition: IDF 2013 Diabetes Atlas -sixth Edition: IDF 2013 Chronic complications
More informationChief of Endocrinology East Orange General Hospital
Targeting the Incretins System: Can it Improve Our Ability to Treat Type 2 Diabetes? Darshi Sunderam, MD Darshi Sunderam, MD Chief of Endocrinology East Orange General Hospital Age-adjusted Percentage
More informationManaging Perioperative Diabetes What s new? Kathryn A. Myers MD FRCPC Chair Chief Division of GIM Professor of Medicine Western University
Managing Perioperative Diabetes What s new? Kathryn A. Myers MD FRCPC Chair Chief Division of GIM Professor of Medicine Western University Objectives: By the end of this session, you will be able to: Identify
More informationGLP-1 agonists. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK
GLP-1 agonists Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What do GLP-1 agonists do? Physiology of postprandial glucose regulation Meal ❶ ❷ Insulin Rising plasma
More information9/29/ Disclosure. Learning Objectives. Diabetes Update: Guidelines, Treatment Options & Trends
+ Diabetes Update: Guidelines, Treatment Options & Trends Melissa Max, PharmD, BC-ADM, CDE Assistant Professor of Pharmacy Practice Harding University College of Pharmacy + Disclosure Conflicts Of Interest
More informationIMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS
IMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS Dr Bidhu Mohapatra, MBBS, MD, FRACP Consultant Physician Endocrinology and General Medicine Introduction 382 million people affected by diabetes
More informationIncredible Incretins Abby Frye, PharmD, BCACP
Incredible Incretins Abby Frye, PharmD, BCACP Objectives & Disclosures Review the pathophysiology of T2DM and the impact of the incretin system Describe the defining characteristics of the available glucagonlike
More information6/1/2018. Lou Haenel, IV, DO, FACE, FACOI Endocrinology Roper St Francis Charleston, SC THE OMINOUS OCTET: HOW PATHOPHYSIOLOGY AND THERAPY MERGE
Lou Haenel, IV, DO, FACE, FACOI Endocrinology Roper St Francis Charleston, SC THE OMINOUS OCTET: HOW PATHOPHYSIOLOGY AND THERAPY MERGE 1 2 3 Sulfonylureas Glipizide Glyburide Glimeperide 4 Metformin Gold
More informationPractical Strategies for the Clinical Use of Incretin Mimetics CME/CE. CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010
Practical Strategies for the Clinical Use of Incretin Mimetics CME/CE Robert R. Henry, MD Authors and Disclosures CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010 Introduction Type 2 diabetes
More informationType 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions
Diabetes Mellitus: Complications and Co-Morbid Conditions ADA Guidelines for Glycemic Control: 2016 Retinopathy Between 2005-2008, 28.5% of patients with diabetes 40 years and older diagnosed with diabetic
More informationGlucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol
Glucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed
More informationWhat s New in Type 2 Diabetes? 2018 Diabetes Updates
What s New in Type 2 Diabetes? 2018 Diabetes Updates Jessica Conklin, PharmD, PhC, BCACP, CDE, AAHIP Associate Professor, UNM College of Phar macy jeconklin@salud.unm.edu Luis Gonzales, PharmD, PhC UNM
More informationNon-insulin treatment in Type 1 DM Sang Yong Kim
Non-insulin treatment in Type 1 DM Sang Yong Kim Chosun University Hospital Conflict of interest disclosure None Committee of Scientific Affairs Committee of Scientific Affairs Insulin therapy is the mainstay
More informationHelp the Heart. An Update on GLP-1 Agonists and SGLT2 Inhibitors. Tara Hawley, PharmD PGY1 Pharmacy Resident Mayo Clinic Health System Eau Claire
Help the Heart An Update on GLP-1 Agonists and SGLT2 Inhibitors Tara Hawley, PharmD PGY1 Pharmacy Resident Mayo Clinic Health System Eau Claire Mayo Clinic Grand Rounds May 16, 2017 2017 MFMER slide-1
More informationWayne Gravois, MD August 6, 2017
Wayne Gravois, MD August 6, 2017 Americans with Diabetes (Millions) 40 30 Source: National Diabetes Statistics Report, 2011, 2017 Millions 20 10 0 1980 2009 2015 2007 - $174 Billion 2015 - $245 Billion
More informationNewer Therapies for Type 2 Diabetes
Newer Therapies for Type 2 Diabetes Sandra Indacochea Sobel, MD Clinical Assistant Professor of Medicine Clinical Chief of Endocrinology, UPMC Mercy Division of Endocrinology, Diabetes, and Metabolism
More informationMOA: Long acting glucagon-like peptide 1 receptor agonist
Alexandria Rydz MOA: Long acting glucagon-like peptide 1 receptor agonist Increases glucose dependent insulin secretion Decreases inappropriate glucagon secretion Increases β- cell growth and replication
More information01/09/2017. Outline. SGLT 2 inhibitor? Diabetes Patients: Complex and Heterogeneous. Association between diabetes and cardiovascular events
MICROVASCULAR COMPLICATIONS Incidence of outcome g 1 Cardioprotective Effects of SGLT2s Relevant for Which T2 Diabetes Patient? SGLT 2 inhibitor? 58 year old, waist circumference 5 cm, PMH: IHD On statin,
More informationPeter Stein, MD Janssen Research and Development
New Agents and Technologies in the Pipeline for the Treatment of Patients with Diabetes Peter Stein, MD Janssen Research and Development Agents in Phase 3 Development for T2DM Long-acting GLP-1 analogues
More informationLa lezione dei trials di safety cardiovascolare. Edoardo Mannucci
La lezione dei trials di safety cardiovascolare Edoardo Mannucci Conflitti di interessi Negli ultimi due anni, E. Mannucci ha ricevuto compensi per relazioni e/o consulenze da: Abbott, AstraZeneca, Boehringer
More informationDiabete: terapia nei pazienti a rischio cardiovascolare
Diabete: terapia nei pazienti a rischio cardiovascolare Giorgio Sesti Università Magna Graecia di Catanzaro Cardiovascular mortality in relation to diabetes mellitus and a prior MI: A Danish Population
More informationDiabetes and Heart Failure: The Role of SGLT2 Inhibitors
22 nd Annual Heart Failure 2018 Symposium Diabetes and Heart Failure: The Role of SGLT2 Inhibitors Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Elliot Corday Professor of Cardiovascular Medicine UCLA Division
More informationExploring Non-Insulin Therapies in Type 1 Diabetes
Exploring Non-Insulin Therapies in Type 1 Diabetes Susan Cornell, BS, PharmD, CDE, FAPhA, FAADE Associate Professor Midwestern University - Chicago College of Pharmacy Disclosures Dr. Cornell: Advanced
More informationDrug Class Monograph
Drug Class Monograph Class: Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drugs: Farxiga (dapagliflozin), Invokamet (canagliflozin/metformin), Invokana (canagliflozin), Jardiance (empagliflozin),
More informationWhat s New in Diabetes Treatment. Disclosures
What s New in Diabetes Treatment Shiri Levy M.D. Henry Ford Hospital Senior Staff Physician Service Chief, West Bloomfield Hospital Endocrinology, Metabolism, Bone and Mineral Disorders Disclosures None
More informationPreventing Serious Health Consequences of Type 2 Diabetes
Preventing Serious Health Consequences of Type 2 Diabetes The Evidence Hertzel C. Gerstein MD MSc FRCPC Professor and Population Health Institute Chair in Diabetes Research McMaster University and Hamilton
More informationWITH SO MANY NEW CLASSES OF MEDICATIONS OUT THERE
UPDATE ON THE NEW DIABETES MEDICATIONS AND HOW TO INCORPORATE INTO YOUR PRACTICE Amy DeGueme, MD, ECNU Madison Medical Affiliates 3/15/19 WITH SO MANY NEW CLASSES OF MEDICATIONS OUT THERE Which ones to
More informationInsulin Initiation and Intensification. Disclosure. Objectives
Insulin Initiation and Intensification Neil Skolnik, M.D. Associate Director Family Medicine Residency Program Abington Memorial Hospital Professor of Family and Community Medicine Temple University School
More informationBasal & GLP-1 Fixed Combination Use
Basal & GLP-1 Fixed Combination Use Michelle M. Mangual, MD Diplomate of the American board of Internal Medicine and Endocrinology, Diabetes and Metabolism San Juan City hospital Learning Objectives o
More informationNavigating the New Options for the Management of Type 2 Diabetes
Navigating the New Options for the Management of Type 2 Diabetes Clinical Associate Professor Mark Kennedy Department of General Practice, University of Melbourne Chair, Primary Care Diabetes Society of
More informationCANVAS Program Independent commentary
CANVAS Program Independent commentary Cliff Bailey Aston University, Birmingham, UK 2017 Disclosures and disclaimers Clifford J Bailey CJB has attended advisory boards, undertaken ad hoc consultancy, received
More informationUKPDS: Over Time, Need for Exogenous Insulin Increases
UKPDS: Over Time, Need for Exogenous Insulin Increases Patients Requiring Additional Insulin (%) 60 40 20 Oral agents By 6 Chlorpropamide years, Glyburide more than 50% of UKPDS patients required insulin
More informationGLP-1-based therapies in the management of type 2 diabetes
GLP-1-based therapies in the management of type 2 diabetes Makbul Aman Mansyur Division Endocrine & Metabolism Department of Internal Medicine Faculty of Medicine Hasanuddin University/ RSUP Dr. Wahidin
More informationUpdate on Agents for Type 2 Diabetes
Update on Agents for Type 2 Diabetes This presentation will: Outline the clinical considerations in the selection of pharmacotherapy for type 2 diabetes, including degree of A1C lowering achieved, patient-specific
More informationTimely!Insulinization In!Type!2! Diabetes,!When!and!How
Timely!Insulinization In!Type!2! Diabetes,!When!and!How, FACP, FACE, CDE Professor of Internal Medicine UT Southwestern Medical Center Dallas, Texas Current Control and Targets 1 Treatment Guidelines for
More informationIn compliance with the accrediting board policies, the American Diabetes Association requires the following disclosure to the participants:
In compliance with the accrediting board policies, the American Diabetes Association requires the following disclosure to the participants: Entity Activity Financial Consideration Comments Novo Nordisk
More informationMedical therapy advances London/Manchester RCP February/June 2016
Medical therapy advances London/Manchester RCP February/June 2016 Advances in medical therapies for diabetes mellitus Duality of interest: The speaker or institutions with which he is associated has received
More informationDiabetes 2013: Achieving Goals Through Comprehensive Treatment. Session 2: Individualizing Therapy
Diabetes 2013: Achieving Goals Through Comprehensive Treatment Session 2: Individualizing Therapy Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism
More informationLet s not sugarcoat it! Update on Pharmacologic Management of Type II DM
Let s not sugarcoat it! Update on Pharmacologic Management of Type II DM Gregory Castelli, PharmD, BCPS, BC-ADM Clinical Pharmacist UPMC St. Margaret Objectives By the end of this presentation, participants
More informationExploring Non-Insulin Therapies in Type 1 Diabetes. Objectives. Pre-Assessment Question #1. Disclosures
Exploring Non-Insulin Therapies in Type 1 Diabetes Disclosures Dr. Cornell: Advanced Practitioner Advisory Board and Speakers Bureau: Novo Nordisk Susan Cornell, BS, PharmD, CDE, FAPhA, FAADE Associate
More information10/15/18. Clinical Updates for Nurse Practitioners and Physician Assistants: Faculty. Disclosures
Clinical Updates for Nurse Practitioners and Physician Assistants: 2018 Combination Basal Insulin and GLP-1 RA Therapy: A Physiologic Approach to Diabetes Care Faculty Robert S. Busch, MD, FACE Director
More informationNew Drug Evaluation: lixisenatide injection, subcutaneous
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationGLP-1 (glucagon-like peptide-1) Agonists (Byetta, Bydureon, Tanzeum, Trulicity, Victoza ) Step Therapy and Quantity Limit Criteria Program Summary
OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) s (Byetta/exenatide, Bydureon/ exenatide extended-release, Tanzeum/albiglutide, Trulicity/dulaglutide, and Victoza/liraglutide) Step Therapy
More informationAdvances in Outpatient Diabetes Care: Algorithms for Care and the Role of Injectable Therapies. Module D
Advances in Outpatient Diabetes Care: Algorithms for Care and the Role of Injectable Therapies Module D 1 Learning Objectives Apply the principles of the comprehensive diabetes algorithms to patients with
More informationUpdate on Cardiovascular Outcome Trials in Diabetes Jay S. Skyler, MD, MACP
Update on Cardiovascular Outcome Trials in Diabetes Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research InsAtute University of Miami Miller School of Medicine
More informationCV outcomes Studies and Implications for diabetes management. Seraj Abualnaja, MD, FRCPC Consultant Interventional cardiologist DSFH
CV outcomes Studies and Implications for diabetes management Seraj Abualnaja, MD, FRCPC Consultant Interventional cardiologist DSFH Case 49 y female with the following medical problems DM typ2 Hypertension
More informationTherapeutic strategy to reduce Glucagon secretion
Clinical focus on glucagon: α-cell as a companion of β-cell Therapeutic strategy to reduce Glucagon secretion Sunghwan Suh Dong-A University Conflict of interest disclosure None Committee of Scientific
More informationCan Treating Diabetes with SGLT2 inhibitors Prevent Heart Failure?
UCSD Hawaii 2017 Symposium Can Treating Diabetes with SGLT2 inhibitors Prevent Heart Failure? Gregg C. Fonarow, MD, FACC, FAHA Elliot Corday Professor of Cardiovascular Medicine UCLA Division of Cardiology
More informationsitagliptin, 25mg, 50mg and 100mg film-coated tablets (Januvia ) SMC No. (1083/15) Merck Sharp and Dohme UK Ltd
sitagliptin, 25mg, 50mg and 100mg film-coated tablets (Januvia ) SMC No. (1083/15) Merck Sharp and Dohme UK Ltd 07 August 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationDIABETES UPDATE 2018
DIABETES UPDATE 2018 Jerome V. Tolbert, M.D., Ph.D. Assistant Professor of Medicine Icahn School of Medicine at Mt. Sinai Division of Endocrinology and Bone Diseases 317 East 17 th Street New York, New
More informationVery Practical Tips for Managing Type 2 Diabetes
Very Practical Tips for Managing Type 2 Diabetes Jean-François Yale, MD, FRCPC McGill University Health Centre, Montreal, Canada Jean-francois.yale@mcgill.ca www.dryale.ca OBJECTIVES DISCLOSURES The participant
More informationPharmacology Update for the Adult Patient - Newer Oral Medications for Diabetes
Pharmacology Update for the Adult Patient - Newer Oral Medications for Diabetes Brooke Hudspeth, PharmD, CDE, MLDE Director of Diabetes Prevention, Kroger Pharmacy Adjunct Assistant Professor, University
More informationEmerging Challenges in Primary Care: GLP-1 Receptor Agonists: New Insights and New Strategies for Successful Long-Term Diabetes Management
Emerging Challenges in Primary Care: 2017 GLP-1 Receptor Agonists: New Insights and New Strategies for Successful Long-Term Diabetes Management 1 Faculty Richard S. Beaser, MD Senior Staff Physician, Medical
More informationManagement of Diabetes
Management of Diabetes Mellitus: Which Drugs for Which Patients? Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu Disclosure No relevant financial relationships
More informationClinical Relevance of Blood Pressure Lowering Effect of Modern Antidiabetic Drugs
Clinical Relevance of Blood Pressure Lowering Effect of Modern Antidiabetic Drugs Professor Guntram Schernthaner Medical University of Vienna, Austria guntram.schernthaner@meduniwien.ac.at Agenda Glucose
More informationCardiologists and HbA1c: Novel Diabetes Drugs and Cardiovascular Disease Outcomes
Biomarkers 2018 Cardiologists and HbA1c: Novel Diabetes Drugs and Cardiovascular Disease Outcomes Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Elliot Corday Professor of Cardiovascular Medicine UCLA Division
More informationAntihyperglycemic Agents in Diabetes. Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014
Antihyperglycemic Agents in Diabetes Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014 Objectives Review 2014 ADA Standards of Medical Care in DM as they
More informationEndocrinologist Sweetgrass Endocrinology
Endocrinologist Sweetgrass Endocrinology Sanders, Cummings Ask Justice Department to Investigate Insulin Prices The Department of Justice and the FTC are asked to investigate whether Lilly, Novo Nordisk,
More informationGLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS FOR TYPE 2 DIABETES: A COMPREHENSIVE
ENDOCRINE PRACTICE Rapid Electronic Article in Press Rapid Electronic Articles in Press are preprinted manuscripts that have been reviewed and accepted for publication, but have yet to be edited, typeset
More informationDipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Prior Authorization Protocol
Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed
More informationUpdates in Diabetes Care
Updates in Diabetes Care Disclosures Nothing to disclose Pharmacist Objectives 1. List strategies for improving diabetes care 2. Understand benefits and risks associated with newer pharmacotherapeutic
More informationIntensifying Treatment Beyond Monotherapy in T2DM: Where Do Newer Therapies Fit?
Intensifying Treatment Beyond Monotherapy in T2DM: Where Do Newer Therapies Fit? Vanita R. Aroda, MD Scientific Director & Physician Investigator MedStar Community Clinical Research Center MedStar Health
More informationLearning and Earning with Gateway Professional Education CME/CEU Webinar Series. Diabetes Update July 6, :00pm 1:00pm
Learning and Earning with Gateway Professional Education CME/CEU Webinar Series Diabetes Update July 6, 2017 12:00pm 1:00pm Jennifer Pennock Holst, MD Endocrinology, Diabetes & Metabolism AHN Center for
More information